Deciphera Pharmaceuticals Secures $15,000,000 Series B Financing

  • Feed Type
  • Date
    1/5/2016
  • Company Name
    Deciphera Pharmaceuticals
  • Mailing Address
    1601 Trapelo Road Waltham, MA 02451 USA
  • Company Description
    Deciphera Pharmaceuticals, LLC was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce best-in-class small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform.
  • Website
    http://www.deciphera.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $15,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    SV Life Sciences’ investment will contribute to rapid progression of Deciphera’s lead tumor-targeting clinical programs, including Altiratinib and DCC-2618, as well as its immuno-targeted therapies such as DCC-3014 and Rebastanib, offering the potential to provide patients with innovative new therapeutic options while building a strong oncology-focused biotechnology company.
  • M&A Terms
  • Venture Investor
    SV Life Sciences